ImmunoCellular Therapeutics (IMUC)., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers.
IMUC’s lead product candidate is ICT-107, a dendritic cell (DC) immunotherapy targeting cancer stem cells (CSCs) and cancer antigens, which is in Phase III clinical trials for the treatment of glioblastoma
IMUC is also developing ICT-140, a DC-based immunotherapy targeting CSCs and cancer antigens that is in Phase I clinical trials for the treatment of ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs, which is in Phase I clinical trials to treat recurrent GBM and other solid tumor cancers.
In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer.
The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.
April 16, 2018
RegMed Investors’ (RMi) pre-open: a bounce is upon us?
April 13, 2018
RegMed Investors’ (RMi) closing bell; the sector slipped
April 12, 2018
RegMed Investors’ (RMi) closing bell; the force was with the sector
April 12, 2018
RegMed Investors’ (RMi) pre-open: reap the harvest of the upside, sell or buy into capricious strength?
April 11, 2018
RegMed Investors’ (RMi) closing bell; sector pricing withers
April 10, 2018
RegMed Investors’ (RMi) closing bell; chugging along
April 9, 2018
RegMed Investors’ (RMi) closing bell; enjoying the high
April 9, 2018
RegMed Investors’ (RMi) pre-open: sector bounce back with news
April 6, 2018
RegMed Investors’ (RMi) closing bell; the newest of new lows
April 5, 2018
RegMed Investors’ (RMi) closing bell; swimming with piranhas
35 companies, 1 interpreter!
Insight, foresight and recommendation
ImmunoCellular Therapeutics (IMUC) -- Always a disappointment having oipened 1/2 at $0.34, cresting to $0.25 on 2/1 closing 2/16 at $0.24. Just another day traders toy ... it's also still in a research mode - stay away.
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors